Fig. 4: Progression-free survival.
CI confidence interval, ERd elotuzumab plus lenalidomide and dexamethasone, HR hazard ratio, PFS progression-free survival, Rd lenalidomide and dexamethasone.
Fig. 4: Progression-free survival. | Blood Cancer Journal
